Anthracycline cardiotoxicity

Expert Opinion on Drug Safety

Volumn 5, Issue 6, 2006, Pages 791-809

  Jones, Robin L ^a   Swanton, Charles ^a,b   Ewer, Michael S ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracycline chemotherapy; Cardiotoxicity; Dexrazoxane; Liposomal anthracycline; Mitoxantrone

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMILORIDE; AMSACRINE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; FUROSEMIDE; IDARUBICIN; METOLAZONE; METOPROLOL SUCCINATE; MITOXANTRONE; MYOSIN ANTIBODY IN 111; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; RAZOXANE; TECHNETIUM 99M; TRASTUZUMAB; TROPONIN T; UNINDEXED DRUG; VALSARTAN;

AGE; BLOOD PRESSURE MONITORING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE REGIMEN; ECG ABNORMALITY; ETHNOLOGY; FETOTOXICITY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MYOCARDITIS; PATIENT IDENTIFICATION; PERICARDITIS; QT PROLONGATION; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SUDDEN DEATH; SYSTEMATIC REVIEW;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; HEART; HEART DISEASES; HUMANS;

EID: 33750564785     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.6.791     Document Type: Review

References (222)

1. LEFRAK EA, PITHA J, ROSENHEIM S, GOTTLIEB JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer (1973) 32:302-314.
2. VON HOFF DD, LAYARD MW, BASA P et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. (1979) 91:710-717.
3. TAN C, TASAKA H, YU KP, MURPHY ML, KARNOFSKY DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer (1967) 20:333-353.
4. BONADONNA G, MONFARDINI S: Cardiac toxicity of daunorubicin. Lancet (1969) 1:837.
5. DI MARCO A, GAETANI M, SCARPINATO B: Adriamycin (NSC-123, 127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. (1969) 53:33-37.
6. PRAGA C, BERETTA G, VIGO PL et al.: Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat. Rep. (1979) 63:827-834.
7. HARRISON DT, SANDERS LA: Pericarditis in a case of early daunorubicin cardiomyopathy. Ann. Intern. Med. (1976) 85:339-341.
8. MANCUSO L, MARCHI S, CANONICO A: Dynamic left ventricular outflow obstruction and myocardial infarction following doxorubicin administration in a woman affected by unsuspected hypertrophic cardiomyopathy. Cancer Treat. Rep. (1985) 69:241-244.
9. STEINBERG JS, COHEN AJ, WASSERMAN AG, COHEN P, ROSS AM: Acute arrhythmogenicity of doxorubicin administration. Cancer (1987) 60:1213-1218.
10. O'BRYAN RM, LUCE JK, TALLEY RW, GOTTLIEB JA, BAKER LH, BONADONNA G: Phase II evaluation of adriamycin in human neoplasia. Cancer (1973) 32:1-8.
11. WORTMAN JE, LUCAS VS Jr, SCHUSTER E, THIELE D, LOGUE GL: Sudden death during doxorubicin administration. Cancer (1979) 44:1588-1591.
12. MINOW RA, BENJAMIN RS, LEE ET, GOTTLIEB JA: Adriamycin cardiomyopathy-risk factors. Cancer (1977) 39:1397-1402.
13. LIPSHULTZ SE, LIPSITZ SR, SALLAN SE et al.: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. (2005) 23:2629-2636.
14. STEINHERZ LJ, STEINHERZ PG, TAN CT, HELLER G, MURPHY ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (1991) 266:1672-1677.
15. STEINHERZ LJ, STEINHERZ PG, TAN C: Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med. Pediatr. Oncol. (1995) 24:352-361.
16. LIPSHULTZ SE, COLAN SD, GELBER RD, PEREZ-ATAYDE AR, SALLAN SE, SANDERS SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. (1991) 324:808-815.
17. 10. Cancer Treat. Rep. (1978) 62:887-891.
18. BRISTOW MR, BILLINGHAM ME, MASON JW, DANIELS JR: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. (1978) 62:873-879.
19. BRISTOW MR, MASON JW, BILLINGHAM ME, DANIELS JR: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann. Intern. Med. (1978) 88:168-175.
20. BILLINGHAM ME, BRISTOW MR, GLATSTEIN E, MASON JW, MASEK MA, DANIELS JR: Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am. J. Surg. Pathol. (1977) 1:17-23.
21. GILLADOGA AC, MANUEL C, TAN CT, WOLLNER N, STERNBERG SS, MURPHY ML: The cardiotoxicity of adriamycin and daunomycin in children. Cancer (1976) 37:1070-1078.
22. PROUT MN, RICHARDS MJ, CHUNG KJ, JOO P, DAVIS HL Jr: Adriamycin cardiotoxicity in children: case reports, literature review, and risk factors. Cancer (1977) 39:62-65.
23. MERRILL J, GRECO FA, ZIMBLER H, BRERETON HD, LAMBERG JD, POMEROY TC: Adriamycin and radiation: synegistic cardiotoxicity. Ann. Intern. Med. (1975) 82:122-123.
24. PIHKALA J, SAARINEN UM, LUNDSTROM U et al.: Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur. J. Cancer (1996) 32A:97-103.
25. MINOW RA, GOTTLIEB JA: Adriamycin cardiotoxicity. Ann. Intern. Med. (1975) 82:855-856.
26. RINEHART JJ, LEWIS RP, BALCERZAK SP: Adriamycin cardiotoxicity in man. Ann. Intern. Med. (1974) 81:475-478.
27. KRISCHER JP, EPSTEIN S, CUTHBERTSON DD, GOORIN AM, EPSTEIN ML, LIPSHULTZ SE: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. (1997) 15:1544-1552.
28. LIPSHULTZ SE, LIPSITZ SR, MONE SM et al.: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. (1995) 332:1738-1743.
29. SILBER JH, JAKACKI RI, LARSEN RL, GOLDWEIN JW, BARBER G: Increased risk of cardiac dysfunction after anthracyclines in girls. Med. Pediatr. Oncol. (1993) 21:477-479.
30. EWER MS, JAFFE N, RIED H, ZIETZ HA, BENJAMIN RS: Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Med. Pediatr. Oncol. (1998) 31:512-515.
31. GIANTRIS A, ABDURRAHMAN L, HINKLE A, ASSELIN B, LIPSHULTZ SE: Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. (1998) 27:53-68.
32. HASAN S, DINH K, LOMBARDO F, KARK J: Doxorubicin cardiotoxicity in African Americans. J. Natl. Med. Assoc. (2004) 96:196-199.
33. DOYLE JJ, NEUGUT AI, JACOBSON JS, GRANN VR, HERSHMAN DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol. (2005) 23:8597-8605.
34. BENJAMIN RS, WIERNIK PH, BACHUR NR: Adriamycin: anew effective agent in the therapy of disseminated sarcomas. Med. Pediatr. Oncol. (1975) 1:63-76.
35. KIM YD, LEES DE, LAKE CR et al.: Hyperthermia potentiates doxorubicin-related cardiotoxic effects. JAMA (1979) 241:1816-1817.
36. SWAIN SM, WHALEY FS, EWER MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 97:2869-2879.
37. PEREZ EA, SUMAN VJ, DAVIDSON NE et al.: Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J. Clin. Oncol. (2004) 22:3700-3704.
38. SHAPIRO CL, HARDENBERGH PH, GELMAN R et al.: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. (1998) 16:3493-3501.
39. ZAMBETTI M, MOLITERNI A, MATERAZZO C et al.: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol. (2001) 19:37-43.
40. KREMER LC, VAN DALEN EC, OFFRINGA M, VOUTE PA: Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. (2002) 13:503-512.
41. KREMER LC, VAN DER PAL HJ, OFFRINGA M, VAN DALEN EC, VOUTE PA: Frequency and risk factors of subdinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. (2002) 13:819-829.
42. LIMAT S, DEMESMAY K, VOILLAT L et al.: Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann. Oncol. (2003) 14:277-281.
43. NOUSIAINEN T, JANTUNEN E, VANNINEN E, HARTIKAINEN J: Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br. J. Cancer (2002) 86:1697-1700.
44. VON HOFF DD, ROZENCWEIG M, LAYARD M, SLAVIK M, MUGGIA FM: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. (1977) 62:200-208.
45. GOORIN AM, CHAUVENET AR, PEREZ-ATAYDE AR, CRUZ J, MCKONE R, LIPSHULTZ SE: Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J. Pediatr. (1990) 116:144-147.
46. SORENSEN K, LEVITT GA, BULL C, DORUP I, SULLIVAN ID: Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer (2003) 97:1991-1998.
47. NYSOM K, HOLM K, LIPSITZ SR et al.: Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. (1998) 16(2):545-550.
48. PEIN F, SAKIROGLU O, DAHAN M et al.: Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br. J. Cancer (2004) 91:37-44.
49. BROUWER CA, GIETEMA JA, VAN DEN BERG MP et al.: Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann. Oncol. (2006) (Epub ahead of print).
50. KREMER LC, VAN DALEN EC, OFFRINGA M, OTTENKAMP J, VOUTE PA: Anthracycline-induced clinic heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol. (2001) 19:191-196.
51. SORENSEN K, LEVITT G, SEBAG-MONTEFIORE D, BULL C, SULLIVAN I: Cardiac function in Wilms' tumor survivors. J. Clin. Oncol. (1995) 13:1546-1556.
52. GANZ WI, SRIDHAR KS, GANZ SS, GONZALEZ R, CHAKKO S, SERAFINI A: Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology (1996) 53:461-470.
53. MCKILLOP JH, BRISTOW MR, GORIS ML, BILLINGHAM ME, BOCKEMUEHL K: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am. Heart J. (1983) 106:1048-1056.
54. EWER MS: Exercise echocardiography reflects cumulative anthracycline exposure during childhood. Pediatr. Blood Cancer (2004) 42:554-555.
55. SCHWARTZ RG, MCKENZIE WB, ALEXANDER J et al.: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am. J. Med. (1987) 82:1109-1118.
56. DRUCK MN, GULENCHYN KY, EVANS WK et al.: Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer (1984) 53:1667-1674.
57. ALEXANDER J, BERGER HJ, ZARET BL: Testing for doxorubicin cardiotoxicity. N. Engl. J. Med. (1979) 300:1393.
58. ALEXANDER J, DAINIAK N, BERGER HJ et al.: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N. Engl. J. Med. (1979) 300(6):278-283.
59. GOTTDIENER JS, MATHISEN DJ, BORER JS et al.: Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann. Intern. Med. (1981) 94:430-435.
60. RITCHIE JL, SINGER JW, THORNING D, SORENSEN SG, HAMILTON GW: Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer (1980) 46:1109-1116.
61. MORGAN GW, MCILVEEN BM, FREEDMAN A, MURRAY IP: Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treat. Rep. (1981) 65:629-638.
62. JAKACKI RI, LARSEN RL, BARBER G, HEYMAN S, FRIDMAN M, SILBER JH: Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening. Cancer (1993) 72:2739-2745.
63. SORENSEN K, LEVITT G, BULL C, CHESSELLS J, SULLIVAN I: Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J. Clin. Oncol. (1997) 15:61-68.
64. HUTTER JJ Jr, SAHN DJ, WOOLFENDEN JM, CARNAHAN Y: Evaluation of the cardiac effects of doxorubicin by serial echocardiography. Am. J. Dis. Child. (1981) 135:653-657.
65. KUECHERER HF, RUFFMANN K, SCHAEFER E, KUEBLER W: Doppler echocardiographic assessment of left ventricular filling dynamics in patients with coronary heart disease and normal systolic function. Eur. Heart J. (1988) 9:649-656.
66. ZARICH SW, ARBUCKLE BE, COHEN LR, ROBERTS M, NESTO RW: Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J. Am. Coll. Cardiol. (1988) 12:114-120.
67. STODDARD MF, SEEGER J, LIDDELL NE, HADLEY TJ, SULLIVAN DM, KUPERSMITH J: Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J. Am. Coll. Cardiol. (1992) 20:62-69.
68. EWER MS, ALI MK, GIBBS HR et al.: Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta. Oncol. (1994) 33:645-649.
69. SUNG RY, HUANG GY, SHING MK et al.: Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int. J. Cardiol. (1997) 60:239-248.
70. TJEERDSMA G, MEINARDI MT, VAN DER GRAAF WT et al.: Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart (1999) 81:419-423.
71. DORUP I, LEVITT G, SULLIVAN I, SORENSEN K: Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart (2004) 90:1214-1216.
72. BAUCH M, ESTER A, KIMURA B, VICTORICA BE, KEDAR A, PHILLIPS MI: Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer (1992) 69:1492-1497.
73. NOUSIAINEN T, VANNINEN E, JANTUNEN E et al.: Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J. Intern. Med. (2002) 251:228-234.
74. NOUSIAINEN T, VANNINEN E, JANTUNEN E et al.: Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin. Sci. (Lond.) (2001) 101:601-607.
75. RUSKOAHO H: Atrial natriuretic peptide: synthesis, release, and metabolism. pharmacol. Rev. (1992) 44:479-602.
76. LEVIN ER, GARDNER DG, SAMSON WK: Natriuretic peptides. N. Engl. J. Med. (1998) 339:321-328.
77. NOUSIAINEN T, JANTUNEN E, VANNINEN E, REMES J, VUOLTEENAHO O, HARTIKAINEN J: Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur. J. Haematol. (1999) 62:135-141.
78. DAUGAARD G, LASSEN U, BIE P et al.: Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur. J. Heart Fail. (2005) 7:87-93.
79. SANDRI MT, SALVATICI M, CARDINALE D et al.: N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin. Chem. (2005) 51:1405-1410.
80. TIKANOJA T, RIIKONEN P, PERKKIO M, HELENIUS T: Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med. Pediatr. Oncol. (1998) 31:73-78.
81. SUZUKI T, HAYASHI D, YAMAZAKI T et al.: Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. (1998) 136:362-363.
82. CIOTTI R, UCCI G, BELOTTI G et al.: Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it? J. Clin. Oncol. (2001) 19:4269-4270.
83. MEINARDI MT, VAN VELDHUISEN DJ, GIETEMA JA et al.: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. (2001) 19:2746-2753.
84. GERMANAKIS I, KALMANTI M, PARTHENAKIS F et al.: Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int. J. Cardiol. (2006) 108:212-215.
85. HORACEK JM, PUDIL R, TICHY M et al.: The use of biochemical markers in cardiotoxicity monitoring inpatients treated for leukemia. Neoplasma (2005) 52:430-434.
86. CARDINALE D, SANDRI MT, MARTINONI A et al.: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. (2000) 36:517-522.
87. CARDINALE D, SANDRI MT, MARTINONI A et al.: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann. Oncol. (2002) 13:710-715.
88. KREMER LC, BASTIAANSEN BA, OFFRINGA M et al.: Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur. J. Cancer (2002) 38:686-689.
89. SANDRI MT, CARDINALE D, ZORZINO L et al.: Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin. Chem. (2003) 49:248-252.
90. LIPSHULTZ SE, RIFAI N, SALLAN SE et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 96:2641-2648.
91. MISSOV E, CALZOLARI C, DAVY JM, LECLERCQ F, ROSSI M, PAU B: Cardiac troponin I in patients with hematologic malignancies. Coron. Artery Dis. (1997) 8:537-541.
92. KILICKAP S, BARISTA I, AKGUL E et al.: cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann. Oncol. (2005) 16:798-804.
93. YAMASHITA J, OGAWA M, SHIRAKUSA T: Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int. J. Cancer (1995) 62:542-547.
94. BILLINGHAM ME, MASON JW, BRISTOW MR, DANIELS JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. (1978) 62:865-872.
95. EWER MS, ALI MK, MACKAY B et al.: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J. Clin. Oncol. (1984) 2:112-117.
96. ISNER JM, FERRANS VJ, COHEN SR et al.: Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am. J. Cardiol. (1983) 51:1167-1174.
97. KREMER LC, TIEL-VAN BUUL MM, UBBINK MC et al.: Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children. J. Clin. Oncol. (1999) 17:1208.
98. ESTORCH M, CARRIO I, MARTINEZ-DUNCKER D et al.: Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J. Clin. Oncol. (1993) 11:1264-1268.
99. ESTORCH M, CARRIO I, BERNA L et al.: Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J. Nucl. Med. (1990) 31:1965-1969.
100. 111In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Morphological and hemodynamic findings. Circulation (1992) 86:1965-1972.
101. CARRIO I, ESTORCH M, BERNA L, LOPEZ-POUSA J, TABERNERO J, TORRES G: Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J. Nucl. Med. (1995) 36:2044-2049.
102. CARRIO I, LOPEZ-POUSA A, ESTORCH M et al.: Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J. Nucl. Med. (1993) 34:1503-1507.
103. ESTORCH M, CARRIO I, MARTINEZ-DUNCKER D et al.: Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J. Clin. Oncol. (1993) 11:1264-1268.
104. CARRIO I, ESTORCH M, BERNA L et al.: Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur. J. Nucl. Med. (1991) 18:806-812.
105. NARULA J, STRAUSS HW, KHAW BA: Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence. J. Nucl. Med. (1993) 34:1507-1509.
106. VALDES OLMOS RA, TEN BOKKEL HUININK WW, TEN HOEVE RF et al.: Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction. Ann. Oncol. (1994) 5:617-622.
107. VALDES OLMOS RA, TEN BOKKEL HUININK WW, TEN HOEVE RF et al.: Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur. J. Cancer (1995) 31A:26-31.
108. HAHM S, DRESNER HS, PODWALL D et al.: DNA biomarkers antecede semiquantitative anthracycline cardiomyopathy. Cancer Invest. (2003) 21:53-67.
109. WASSMUTH R, LENTZSCH S, ERDBRUEGGER U et al.: Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am. Heart J. (2001) 141:1007-1013.
110. THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med. (1992) 327:685-691.
111. THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. (1991) 325:293-302.
112. PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1658.
113. NO AUTHORS LISTED: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9-13.
114. NO AUTHORS LISTED: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001-2007.
115. HEIDENREICH PA, LEE TT, MASSIE BM: Effect of beta-blockade on mortality in patients with heart failure: a mete-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1997) 30(1):27-34.
116. LECHAT P, PACKER M, CHALON S, CUCHERAT M, ARAB T, BOISSEL JP: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98:1184-1191.
117. JENSEN BV, NIELSEN SL, SKOVSGAARD T: Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet (1996) 347:297-299.
118. FAZIO S, PALMIERI EA, FERRAVANTE B, BONE F, BIONDI B, SACCA L: Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin. Cardiol. (1998) 21:777-779.
119. NOORI A, LINDENFELD J, WOLFEL E, FERGUSON D, BRISTOW MR, LOWES BD: Beta-blockade in adriamycin-induced cardiomyopathy. J. Card. Fail. (2000) 6:115-119.
120. MUKAI Y, YOSHIDA T, NAKAIKE R et al.: Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern. Med. (2004) 43:1087-1088.
121. SILBER JH, CNAAN A, CLARK BJ et al.: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. (2004) 22:820-828.
122. LIPSHULTZ SE, LIPSITZ SR, SALLAN SE et al.: Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. (2002) 20:4517-4522.
123. NAKAMAE H, TSUMURA K, TERADA Y et al.: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer (2005) 104:2492-2498.
124. LEVITT G, BUNCH K, ROGERS CA, WHITEHEAD B: Cardiac transplantation in childhood cancer survivors in Great Britain. Eur. J. Cancer (1996) 32A:826-830.
125. ARMITAGE JM, KORMOS RL, GRIFFITH BP, FRICKER FJ, HARDESTY RL: Heart transplantation in patients with malignant disease. J. Heart Transplant. (1990) 9:627-629.
126. GRANDE AM, RINALDI M, SINELLI S, D'ARMINI AM, VIGANO M: Heart transplantation in chemotherapeutic dilated cardiomyopathy. Transplant. Proc. (2003) 35:1516-1518.
127. OLSON RD, MUSHLIN PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. (1990) 4:3076-3086.
128. GIANNI L, ZWEIER JL, LEVY A, MYERS CE: Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J. Biol. Chem. (1985) 260:6820-6826.
129. WOLF MB, BAYNES JW: The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta. (2006) 1760:267-271.
130. CHOW AY, CHIN C, DAHL G, ROSENTHAL DN: Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J. Clin. Oncol. (2006) 24:925-928.
131. ZHOU S, STARKOV A, FROBERG MK, LEINO RL, WALLACE KB: Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. (2001) 61:771-777.
132. KOTAMRAJU S, KALIVENDI SV, KONOREV E, CHITAMBAR CR, JOSEPH J, KALYANARAMAN B: Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods Enzymol. (2004) 378:362-382.
133. KOTAMRAJU S, KONOREV EA, JOSEPH J, KALYANARAMAN B: Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Mol. Chem. (2000) 275:33585-33592.
134. KALIVENDI SV, KOTAMRAJU S, ZHAO H, JOSEPH J, KALYANARAMAN B: Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. (2001) 276:47266-47276.
135. NADAL-GINARD B, KAJSTURA J, ANVERSA P, LERI A: A matter of life and death: cardiac myocyte apoptosis and regeneration. J. Clin. Invest. (2003) 111:1457-1459.
136. WANG S, KOTAMRAJU S, KONOREV E, KALIVENDI S, JOSEPH J, KALYANARAMAN B: Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. (2002) 367:729-740.
137. MINOTTI G, MENNA P, SALVATORELLI E, CAIRO G, GIANNI L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. (2004) 56:185-229.
138. FISHER PW, SALLOUM F, DAS A, HYDER H, KUKREJA RC: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation (2005) 111:1601-1610.
139. SIMUNEK T, STERBA M, HOLECKOVA M et al.: Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals (2005) 18:163-169.
140. BRAMBILLA C, ROSSI A, BONFANTE V et al.: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat. Rep. (1986) 70:261-266.
141. JAIN KK, CASPER ES, GELLER NL et al.: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. (1985) 3:818-826.
142. PEREZ DJ, HARVEY VJ, ROBINSON BA et al.: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J. Clin. Oncol. (1991) 9:2148-2152.
143. NO AUTHORS LISTED: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J. Clin. Oncol. (1988) 6:976-982.
144. FRENCH EPIRUBICIN STUDY GROUP: A prospective randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. (1988) 6:679-688.
145. NIELSEN D, JENSEN JB, DOMBERNOWSKY P et al.: Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J. Clin. Oncol. (1990) 8:1806-1810.
146. RYBERG M, NIELSEN D, SKOVSGAARD T, HANSEN J, JENSEN BV, DOMBERNOWSKY P: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. (1998) 16:3502-3508.
147. MEINARDI MT, VAN VELDHUISEN DJ, GIETEMA JA et al.: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. (2001) 19:2746-2753.
148. BONNETERRE J, ROCHE H, KERBRAT P et al.: Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J. Clin. Oncol. (2004) 22:3070-3079.
149. FUMOLEAU P, ROCHE H, KERBRAT P et al.: French Adjuvant Study Group. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann. Oncol. (2006) 17:85-92.
150. LOPEZ M, CONTEGIACOMO A, VICI P et al.: A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer (1989) 64:2431-2436.
151. ANDERLINI P, BENJAMIN RS, WONG FC et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. (1995) 13:2827-2834.
152. TOFFOLI G, SORIO R, AITA P et al.: Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin. Cancer Res. (2000) 6:2279-2287.
153. CRIVELLARI D, LOMBARDI D, CORONA G et al.: Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a Phase II multi-institutional study with pharmacokinetic drug monitoring. Ann. Oncol. (2006) 17:807-812.
154. SHENKENBERG TD, VON HOFF DD: Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med. (1986) 105:67-81.
155. UNVERFERTH DV, UNVERFERTH BJ, BALCERZAK SP, BASHORE TA, NEIDHART JA: Cardiac evaluation of mitoxantrone. Cancer Treat. Rep. (1983) 67:343-350.
156. MATHER FJ, SIMON RM, CLARK GM, VON HOFF DD: Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group Phase II studies. Cancer Treat. Rep. (1987) 71:609-613.
157. CROSSLEY RJ: Clinical safety and tolerance of mitoxantrone. Semin. Oncol. (1984) 11:54-58.
158. VAN DALEN EC, VAN DER PAL HJ, BAKKER PJ, CARON HN, KREMER LC: Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur. J. Cancer (2004) 40:643-652.
159. FORD JM, PANASCI L, LECLERC Y, MARGOLESE R: Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. Cancer Treat. Rep. (1987) 71:921-925.
160. STEWART DJ, PERRAULT DJ, MAROUN JA, LEFEBVRE BM: Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. Am. J. Clin. Oncol. (1987) 10:335-340.
161. JANMOHAMMED R, MILLIGAN DW: Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines. Br. J. Haematol. (1989) 71:292-293.
162. VON HERBAY A, DORKEN B, MALL G, KORBLING M: Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. Klin. Wochenschr. (1988) 66:1175-1181.
163. UMEMOTO M, KAWASAKI H, AZUMA E, KOMADA Y, ITO M, SAKURAI M: Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy. Am. J. Hematol. (1996) 52:327-328.
164. BENEKLI M, KARS A, GULER N: Mitoxantrone-induced bradycardia. Ann. Intern. Med. (1997) 126:409.
165. ROCK E, DEMICHELE A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J. Nutr. (2003) 133:3785S-3793S.
166. 10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol. Aspects Med. (1994) 15: s207-s212.
167. KRAFT J, GRILLE W, APPELT M et al.: Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematol. Blood Transfus. (1990) 33:566-570.
168. MILEI J, MARANTZ A, ALE J, VAZQUEZ A, BUCETA JE: Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv. (1987) 4:129-136.
169. MYERS C, BONOW R, PALMERI S et al.: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. (1983) 10:53-55.
170. WAGDI P, ROUVINEZ G, FLURI M et al.: [Cardioprotection in chemo- and radiotherapy for malignant diseases - an echocardiographic pilot study]. Schweiz. Rundsch. Med. Prax. (1995) 84:1220-1223.
171. VAN DALEN EC, CARON HN, DICKINSON HO, KREMER LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. (2005) 1:CD003917.
172. LI T, SINGAL PK: Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation (2000) 102:2105-2110.
173. STRAUSS M, ANSELMI G, HERMOSO T, TEJERO F: Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model. J. Mol. Cell Cardiol. (1998) 30:2319-2325.
174. YARIS N, CEVIZ N, COSKUN T, AKYTUZ C, BUYUKPAMUKCU M: Serum carnitine
175. DANESI F, MALAGUTI M, NUNZIO MD, MARANESI M, BIAGI PL, BORDONI A: Counteraction of adriamycin-induced oxidative damage in rat heart by selenium dietary supplementation. J. Agric. Food Chem. (2006) 54:1203-1208.
176. LI L, TAKEMURA G, LI Y et al.: Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation (2006) 113:535-543.
177. SAVARESE DM, SAVY G, VAHDAT L, WISCHMEYER PE, COREY B: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat. Rev. (2003) 29:501-513.
178. MUKHERJEE S, BANERJEE SK, MAULIK M, DINDA AK, TALWAR KK, MAULIK SK: Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. (2003) 3:16.
179. WEISS AJ, METTER GE, FLETCHER WS, WILSON WL, GRACE TB, RAMIREZ G: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. (1976) 60:813-822.
180. WEISS AJ, MANTHEL RW: Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer (1977) 40:2046-2052.
181. CHLEBOWSKI RT, PAROLY WS, PUGH RP et al.: Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat. Rep. (1980) 64:47-51.
182. TORTI FM, BRISTOW MR, HOWES AE et al.: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann. Intern. Med. (1983) 99:745-749.
183. VALDIVIESO M, BURGESS MA, EWER MS et al.: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J. Clin. Oncol. (1984) 2:207-214.
184. LEGHA SS, BENJAMIN RS, MACKAY B et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. (1982) 96:133-139.
185. HORTOBAGYI GN, FRYE D, BUZDAR AU et al.: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast Carcinoma. Cancer (1989) 63:37-45.
186. ZALUPSKI M, METCH B, BALCERZAK S et al.: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J. Natl. Cancer Inst. (1991) 83:926-932.
187. LIPSHULTZ SE, GIANTRIS AL, LIPSITZ SR et al.: Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. (2002) 20:1677-1682.
188. LEVITT GA, DORUP I, SORENSEN K, SULLIVAN I: Does anthracycline administration by infusion in children affect late cardiotoxicity? Br. J. Haematol. (2004) 124:463-468.
189. RAJAGOPALAN S, POLITI PM, SINHA BK, MYERS CE: Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. (1988) 48:4766-4769.
190. SPEYER JL, GREEN MD, ZELENIUCH-JACQUOTTE A et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. (1992) 10:117-127.
191. KELLNER U, SEHESTED M, JENSEN PB, GIESELER F, RUDOLPH P: Culprit and victim- DNA topoisomerase II. Lancet Oncol. (2002) 3:235-243.
192. WEXLER LH, ANDRICH MP, VENZON D et al.: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. (1996) 14:362-372.
193. SWAIN SM, WHALEY FS, GERBER MC, EWER MS, BIANCHINE JR, GAMS RA: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. (1997) 15:1333-1340.
194. SWAIN SM, WHALEY FS, GERBER MC et al.: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. (1997) 15:1318-1332.
195. LIPSHULTZ SE, RIFAI N, DALTON VM et al.: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. (2004) 351:145-153.
196. MARTY M, ESPIE M, LLOMBART A, MONNIER A, RAPOPORT BL, STAHALOVA V: Multicenter randomized Phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol. (2006) 17:614-622.
197. SEYMOUR L, BRAMWELL V, MORAN LA: Use of dexrazoxane as a cardioprotectantin patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev. Control (1999) 3:145-159.
198. SCHUCHTER LM, HENSLEY ML, MEROPOL NJ, WINER EP: American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel: 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. (2002) 20:2895-2903.
199. CVETKOVIC RS, SCOTT LJ: Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs (2005) 65:1005-1024.
200. HIGUCHI Y, OTSU K, NISHIDA K et al.: Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J. Mol. Cell Cardiol. (2002) 34:233-240.
201. BOLAND MP, FOSTER SJ, O'NEILL LA: Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J. Biol. Chem. (1997) 272:12952-12960.
202. WANG CY, MAYO MW, BALDWIN AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 274:784-787.
203. TERGAONKAR V, BOTTERO V, IKAWA M, LI Q, VERMA IM: IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol. Cell Biol. (2003) 23:8070-8083.
204. BOLAND MP, FITZGERALD KA, O'NEILL LA: Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J. Biol. Chem. (2000) 275:25231-25238.
205. GABIZON AA: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. (1992) 52:891-896.
206. RIVERA E: Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist (2003) 8:3-9.
207. O'BYRNE KJ, THOMAS AL, SHARMA RA et al.: A Phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br. J. Cancer (2002) 87:15-20.
208. FASSAS A, BUFFELS R, ANAGNOSTOPOULOS A et al.: Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a Phase I-II study. Br. J. Haematol. (2002) 116:308-315.
209. BATIST G, RAMAKRISHNAN G, RAO CS et al.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. (2001) 19:1444-1454.
210. SHAPIRO CL, ERVIN T, WELLES L, AZARNIA N, KEATING J, HAYES DF: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J. Clin. Oncol. (1999) 17:1435-1441.
211. BERRY G, BILLINGHAM M, ALDERMAN E et al.: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. (1998) 9:711-716.
212. 2. Ann. Oncol. (2000) 11:1029-1033.
213. GABIZON AA, LYASS O, BERRY GJ, WILDGUST M: Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. (2004) 22:663-669.
214. O'BRIEN ME, WIGLER N, INBAR M et al.; CAELYX Breast Cancer Study Group: Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. (2004) 15:440-449.
215. CHAN S, DAVIDSON N, JUOZAITYTE E et al.: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann. Oncol. (2004) 15:1527-1534.
216. SEIDMAN A, HUDIS C, PIERRI MK et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. (2002) 20:1215-1221.
217. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
218. CHIA S, CLEMONS M, MARTIN LA et al.: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol. (2006) 24:2773-2778.
219. CARDONICK E, IACOBUCCI A: Use of chemotherapy during human pregnancy. Lancet Oncol. (2004) 5:283-291.
220. PECCATORI F, MARTINELLI G, GENTILINI O, GOLDHIRSCH A: Chemotherapy during pregnancy: what is really safe? Lancet Oncol. (2004) 5:398.
221. AVILES A, NERI N, NAMBO MJ: Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann. Oncol. (2006) 17:286-288.
222. VAN CALSTEREN K, BERTELOOT P, HANSSENS M et al.: In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J. Clin. Oncol. (2006) 24:e16-e17.